S

Sanofi

Global pharma company; vaccines and R&D

Clinical Operations and Study Leader

Full-TimeUpdated on 10/15/2026Deadline 12/31/26
No salary listed
Senior, Expert
Master's
Tokyo, Japan
In Person
Biology & BiotechClinical Research Operations

About the job

Requirements
  • At least a Master's degree in a relevant scientific and/or medical field.
  • At least 8 years of experience in clinical research in the pharmaceutical industry.
  • Very strong project management experience and a proven track record of effectively leading multifunctional teams.
  • Strong project management skills, transversal and strategic leadership capabilities, communication skills, and business acumen.
  • Ability to drive a high-performing cross-functional team that empowers and motivates individual members and the team.
  • Strong interpersonal skills to collaborate effectively with physicians, scientists, and managers from various disciplines and to set and manage expectations.
  • Clinical trial experience.
  • Excellent organizational, interpersonal, and communication skills, both verbal and written.
  • Strong communication skills in the local language and English, with adequate knowledge of local requirements.
  • Customer and quality focus.
  • Capability to handle large, complicated global projects that integrate various disciplines.
  • Proactive approach and ability to drive decision-making.
  • Innovative problem-solving ability.
  • People, change, and influence management skills.
  • Ability to set and manage expectations.
  • Self-motivation, results-driven approach, attention to detail, and good organizational skills.
  • Ability to resolve conflict.
  • Strong negotiation skills.
  • Cultural savvy and leadership in a multicultural environment.
  • Positive mindset and behavior, with strong team spirit.
  • Familiarity with project management software.
Responsibilities
  • Provide operational input into clinical project strategy and expertise to develop the operational and scientific strategy for successful project conduct.
  • Support clinical project governance in collaboration with the Global Clinical Development Strategy Expert.
  • Communicate Clinical Development Plans throughout the Extended Clinical Team and R&D Project Team and ensure alignment with the global R&D project strategy.
  • Ensure clinical project performance meets expectations for timelines, quality, and budget.
  • Harmonize operational strategy among studies within a program and across clinical projects and programs, and align local and global activities.
  • Manage planning and execution feasibility for clinical studies, projects, and programs within the Clinical Development Plan.
  • Plan and drive execution of clinical sections of regulatory submissions, including CTD, eBLA, and PAI submissions, and communicate status updates.
  • Monitor project progress and performance against strategic objectives and key performance indicators.
  • Report program-management progress for clinical trials proactively and promptly, and escalate issues requiring Clinical Management input and discussion.
  • Coordinate clinical teams with the Global Clinical Development Strategy Expert on study operational matters, including organizing study-specific meetings.
  • Ensure study operational feasibility is assessed with other functions and integrate feedback on regulatory timelines, country selection, recruitment potential, budget needs, and risks into the study plan.
  • Coordinate clinical timelines from contributors, including IMP and NIMP updates in the CSC Order Management tool; address potential delays and coordinate plans to meet study timelines.
  • Establish appropriate communication for the Clinical Team.
  • Ensure Trial Management tools are properly set up and study documentation is available with appropriate tool access.
  • Collect, synthesize, and report study information.
  • Participate in vendor and operational-expert selection and management, and develop and follow up on associated budgets when needed.
  • Prepare and follow up on study budgets.
  • Collaborate on preparation and oversight of study audits, pre-approval inspections, and inspections.
  • Consolidate strategic communication at project and program levels and maintain cross-functional communication.
  • Act as an interface between the Extended Clinical and Clinical Teams and enabling functions, including GRA, PSPV, CMQO, GMA, EPI, PPFP, and GI, particularly to resolve issues.
  • Oversee contract research organizations involved in study monitoring.
  • Ensure effective cross-regional and top-down/bottom-up communication so clinical teams can efficiently achieve global plans.
  • Arrange scientific advisory boards, adjudication committees, and expert committees in collaboration with the Global Clinical Development Strategy Expert, including setup, follow-up, communication, and management of expert partnerships and alliances.
  • Participate in R&D project, Extended Clinical, and Clinical Teams for assigned projects.
  • Engage in decision-making with stakeholders in Global Clinical Development and provide input to the Head of Global Clinical Development and global heads of clinical platforms.
  • Provide guidance on operational best practices and lessons learned for clinical-trial execution and facilitate operational issue resolution.
  • Lead risk-management initiatives for clinical projects to minimize negative impacts on team deliverables.
  • Coordinate crisis management within clinical projects and programs and work with Clinical platforms and other groups to define and implement action plans.
  • Mentor team members in collaboration with their managers to develop leadership skills such as consensus-building and conflict resolution, and support team-member empowerment.
  • Plan and manage project-level capacity and resources with other Global Clinical Development functions.
  • Consolidate and review budget and resource allocation for clinical project and study activities through cross-functional reviews, and work with BO, FP, and R&D Finance to ensure clinical budgets and plans are accurate.
  • Track and monitor project and program budgets with support from BO.
  • Support innovation in clinical-trial designs, digital methodologies, tools, and clinical project and program organization.
  • Establish a culture of continuous learning and improvement in the clinical project; identify process issues and propose solutions.
  • Identify opportunities to improve organizational processes and organizational excellence.
  • Build lessons learned into the review and adoption of new approaches and methods.
  • Stay abreast of advances in the area of expertise.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)